We’re pleased to share positive Phase 1 clinical results for STC-004, our lead NaV1.8 inhibitor in development for the non-opioid treatment of pain. Key findings: ? Well-tolerated across all dose levels tested, with favorable safety profile ? Pharmacokinetics data support once-daily dosing ? Strong evidence of target engagement and analgesic potential in an experimental pain model “These compelling phase 1 results reinforce the potential of STC-004 as a transformative, non-opioid solution for pain management,” said @John Mulcahy, Ph.D., CEO of SiteOne Therapeutics. “With these results in hand, we are focused on rapidly advancing STC-004 into Phase 2 trials in the second half of this year.” Read the press release here: https://lnkd.in/gcFFKZcM #nonopioidtherapies #painmanagement #pain #drugdiscovery #ionchannels #biotech
SiteOne Therapeutics, Inc.
生物技术研究
South San Francisco，CA 2,505 位关注者
Transforming the Treatment of Pain
关于我们
SiteOne Therapeutics is a biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting NaV1.7, NaV1.8, and other voltage-gated ion channels to treat sensory hyperexcitability disorders such as chronic cough, itch, and pain. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids. The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain.
- 网站
-
https://siteonetherapeutics.com/
SiteOne Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco，CA
- 类型
- 私人持股
- 创立
- 2010
地点
-
主要
获取路线
US，CA，South San Francisco，94080
SiteOne Therapeutics, Inc.员工
动态
-
We’re excited to announce a $100 million Series C financing to advance our pipeline of selective ion channel modulators as non-opioid treatments for pain and sensory hyperexcitability disorders. Our lead program targets NaV1.8, a promising approach for meaningful analgesia with a reduced risk of abuse. We are also excited to explore the potential of sodium channels and other genetically and clinically validated targets to treat pain and sensory hyperexcitability disorders. Thank you to our investors: Novo Holdings for leading the round, and OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital Inc., and our existing investors for participating. Read the press release here: https://lnkd.in/gSFhUNc9 We also launched a new website! Learn more about how we're "owning the action potential" to deliver innovative therapies: https://lnkd.in/gWFt3pQk #nonopioidtherapies #painmanagement #pain #drugdiscovery #ionchannels #biotech #bayarea #financing #venturecapital
-